Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
FAK inhibitors in cancer, a patent review – an update on progress36
Malaria transmission blocking compounds: a patent review36
Recent developments of agents targeting Vibrio cholerae : patents and literature data35
Update on mGlu4 modulator patents: 2017 to present34
The role of patent analysis in target selection33
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)31
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities30
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature27
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review26
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)24
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present24
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of MAPK inhibitors (2018 – present)22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Inhibition of GTPase KRAS G12D : a review of patent literature19
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)18
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review18
Small-molecule RNA ligands: a patent review (2018–2024)18
Antiprotozoal drugs: challenges and opportunities18
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)17
An updated patent review of MALT1 inhibitors (2021–present)17
A patent review of IDH1 inhibitors (2018-present)16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders15
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)15
Biofilm and bacterial membrane vesicles: recent advances14
A patent and literature review of CDK12 inhibitors14
Antimalarial drugs: what’s new in the patents?14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)13
Dopamine D3 receptor ligands: a patent review (2014–2020)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Are patents important indicators of innovation for Chagas disease treatment?12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
An updated patent review of EZH2 inhibitors (2024–present)12
An updated patent review of TRPA1 antagonists (2020 – present)11
Correction11
The patent review of the biological activity of tropane containing compounds11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)9
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
A patent review of selective CDK9 inhibitors in treating cancer9
A patent review of BRD4 inhibitors (2020–present)9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
A patent review of CXCR7 modulators (2019-present)8
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)8
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)8
Rho kinase inhibitors: a patent review (2017–2023)8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)8
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)8
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)8
A patent perspective of antiangiogenic agents7
Nurr1 modulators – a patent review (2019–present)7
Recent advances in the development of STING inhibitors: an updated patent review7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
An updated patent review on monoamine oxidase (MAO) inhibitors7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)7
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid7
A patent review of xanthine oxidase inhibitors (2021–present)6
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)6
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
Pitfalls in patenting academic CAR-T cells therapy6
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)6
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
BET inhibitors: an updated patent review (2018–2021)5
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
An updated patent review of glutaminase inhibitors (2019–2022)5
A review of the patent literature surrounding TRPV1 modulators5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections5
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
A patent review of adenosine A2Breceptor antagonists (2016-present)5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)5
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)5
CBL-B – An upcoming immune-oncology target5
Recent updates on Wnt signaling modulators: a patent review (2014-2020)5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
Natural products as a source of new anticancer chemotypes5
An updated patent review of BRD4 degraders5
Anticancer drugs: where are we now?5
Proteasome inhibitors as anticancer agents5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
0.050761938095093